The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity.

Genotoxic chemotherapy is the most common cancer treatment strategy. However, its untargeted generic DNA-damaging nature and associated systemic cytotoxicity greatly limit its therapeutic applications. Here, we used a haploid genetic screen in human cells to discover an absolute dependency of the clinically evaluated anticancer compound YM155 on solute carrier family member 35 F2 (SLC35F2), an uncharacterized member of the solute carrier protein family that is highly expressed in a variety of human cancers. YM155 generated DNA damage through intercalation, which was contingent on the expression of SLC35F2 and its drug-importing activity. SLC35F2 expression and YM155 sensitivity correlated across a panel of cancer cell lines, and targeted genome editing verified SLC35F2 as the main determinant of YM155-mediated DNA damage toxicity in vitro and in vivo. These findings suggest a new route to targeted DNA damage by exploiting tumor and patient-specific import of YM155.

[1]  L. Hartwell,et al.  Genetic control of the cell division cycle in yeast. , 1974, Science.

[2]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[3]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[4]  N. Cordes,et al.  Fibronectin Alters Cell Survival and Intracellular Signaling of Confluent A549 Cultures After Irradiation , 2004, Cancer biology & therapy.

[5]  Rudolf Jaenisch,et al.  One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[6]  A. Tolcher,et al.  Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[8]  Douglas B Kell,et al.  Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. , 2011, Drug discovery today.

[9]  D. Sabatini,et al.  MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors , 2012, Nature Genetics.

[10]  D. Sabatini,et al.  A haploid genetic screen identifies the major facilitator domain containing 2A (MFSD2A) transporter as a key mediator in the response to tunicamycin , 2011, Proceedings of the National Academy of Sciences.

[11]  Carla P. Guimarães,et al.  Haploid Genetic Screens in Human Cells Identify Host Factors Used by Pathogens , 2009, Science.

[12]  Jan H. Reilinga,et al.  A Haploid Genetic Screen Identifies the Major Facilitator Domain Containing 2a (mfsd2a) Transporter as a Key Mediator in the Response to Tunicamycin Accessed Terms of Use Detailed Terms , 2022 .

[13]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[14]  M. Kawakita,et al.  Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35) , 2004, Pflügers Archiv.

[15]  H. Kamimura,et al.  Characterization of Human Organic Cation Transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-Mediated Transport of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small Molecule Survivin Suppressant , 2010, Drug Metabolism and Disposition.

[16]  D. Kell,et al.  Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.

[17]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[18]  M. Roth,et al.  Identification of a retroviral receptor used by an Envelope protein derived by peptide library screening , 2007, Proceedings of the National Academy of Sciences.

[19]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[20]  O. Fernandez-Capetillo,et al.  ATR signaling can drive cells into senescence in the absence of DNA breaks. , 2008, Genes & development.

[21]  Hidde L. Ploegh,et al.  Global gene disruption in human cells to assign genes to phenotypes , 2011, Nature Biotechnology.

[22]  D. Newton,et al.  The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response , 2012, Cancer Chemotherapy and Pharmacology.

[23]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Douglas B Kell,et al.  Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast , 2011, BMC Biology.

[25]  David Hsu,et al.  OpenComet: An automated tool for comet assay image analysis , 2014, Redox biology.

[26]  Shigeki Kawabata,et al.  Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin , 2012, Molecular & Cellular Proteomics.

[27]  Kenji Sugimoto,et al.  Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells , 2009, Drug Metabolism and Disposition.

[28]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[29]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[30]  N. Osheroff,et al.  Biological characterization of MLN944: a potent DNA binding agent. , 2004, Molecular cancer therapeutics.

[31]  Zhiwei Song.  Roles of the nucleotide sugar transporters (SLC35 family) in health and disease. , 2013, Molecular aspects of medicine.

[32]  G. Giaccone,et al.  Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Xuegong Zhang,et al.  DEGseq: an R package for identifying differentially expressed genes from RNA-seq data , 2010, Bioinform..

[34]  S. Cohen,et al.  Inhibition of DNA and RNA polymerase reactions by chloroquine. , 1965, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[36]  Wei Li,et al.  RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..